MAUI Imaging Secures $14 Million for Innovative Ultrasound Tech
MAUI Imaging, a pioneer in advanced imaging technology, has successfully raised $14 million in a Series D funding round led by Acertara Acoustic Laboratories. This funding aims to enhance the production and marketing of MAUI's innovative Computed Echo Tomography (CET) technology, which brings a new level of imaging capability beyond conventional ultrasound methods.
MAUI Imaging's CEO and co-founder, David Specht, expressed enthusiasm about the funding, emphasizing the need for more advanced ultrasound systems in trauma medicine. He noted, "This support enables us to address the urgent demand for a versatile ultrasound technology that can effectively image various tissues, particularly in trauma scenarios. Our collaboration with the U.S. military enhances our goal of improving patient care by providing crucial data for emerging AI technologies in medicine."
The company is now delivering its groundbreaking devices to its first users, with Acertara taking the lead on pre-orders across hospitals where MAUI Imaging does not have a direct influence. Levi Moore, President and CEO of Acertara, remarked, "The MAUI ultrasound system represents a significant leap in medical imaging. It simplifies image acquisition and makes ultrasound accessible to a broader range of clinicians. We're dedicated to promoting its adoption in hospitals throughout the country, where this technology could save lives and markedly enhance patient outcomes."
Emerging from its stealth phase in August 2024, MAUI Imaging announced a contract with the U.S. Department of Defense worth $4 million. This contract aims to support trauma medicine initiatives across four military branches, enabling faster diagnostics and care during high-stress, high-volume situations.
Partnership with the U.S. Department of Defense:
The program supported by the U.S. Army Medical Research and Development Command is focused on trauma care advancements and is implemented at the University of Maryland Shock Trauma Center in Baltimore, a prominent center for training military trauma surgeons and healthcare professionals.
A committee of independent expert physicians recently evaluated MAUI Imaging's technology. They concluded that it presents a transformative shift in ultrasound imaging capabilities that could significantly enhance patient management in emergencies, even when other imaging tools are not available. Traditional ultrasound techniques have limitations when addressing cranial and spinal injuries, often requiring CT or MRI scans that may not be readily available. MAUI Imaging seeks to bridge this gap by reducing the time needed for diagnosis and treatment in critical situations.
Importantly, the views and conclusions highlighted represent those of MAUI Imaging and are not affiliated with any official government endorsements or policies.
FDA Clearance for MAUI's Innovative Device:
In October 2023, the MAUI K3900 device received its 510(k) FDA clearance, marking it as commercially available for various healthcare applications. The K3900 is specifically designed for qualified healthcare personnel tasked with ultrasound evaluations across several medical needs, including fetal, abdominal, pediatric, and cardiac assessments.
Among its strengths, MAUI's patented Computed Echo Tomography technique introduces a groundbreaking approach to diagnostic imaging, combining elements of ultrasound and CT without exposing patients to harmful radiation. The system intelligently visualizes anatomy by utilizing unique reflection techniques to gather comprehensive image data from various angles, overcoming barriers typically faced by standard ultrasound systems.
MAUI Imaging's innovative CET method addresses speed-of-sound aberrations in tissues, enabling imaging of previously challenging areas, such as brain and lung tissue. The company holds a robust portfolio with over 160 patents granted, with additional pending applications in the U.S. and globally.
By utilizing a concave probe, which transmits energy from multiple angles, MAUI Imaging's technology surpasses the limitations of traditional ultrasound systems that struggle with barriers in the human body. This advancement allows easier positioning and efficiency in obtaining diagnostic images, thereby reducing the need for invasive procedures. MAUI's technology can process vast datasets rapidly, offering analytical insights that could revolutionize ultrasound diagnostics, especially in conjunction with AI developments.
As hospitals and healthcare centers recognize the potential impact of MAUI Imaging's technology, the company is actively conducting clinical studies to validate its capabilities further.
About MAUI Imaging
MAUI Imaging’s Computed Echo Tomography (CET) is at the forefront of modern diagnostic imaging, utilizing ultrasound to penetrate barriers for swift and effective visualization of the human body. With a foundation of more than 160 patents, MAUI's systems provide extensive datasets that enhance diagnostic processes and patient interventions. Currently, the company is establishing clinical partnerships to explore the application of its innovative technology in trauma care, neurosurgery, and interventional radiology. MAUI Imaging is committed to advancing the efficacy of ultrasound visualization, enabling healthcare personnel to perform complex assessments in real-time without requiring extensive retraining.
Frequently Asked Questions
What is MAUI Imaging's recent funding about?
MAUI Imaging raised $14 million in a Series D funding round to enhance its groundbreaking imaging technology, aiming to advance its production and marketing efforts.
What technology is MAUI Imaging known for?
MAUI Imaging is recognized for its patented Computed Echo Tomography (CET), which offers advanced ultrasound capabilities for imaging various tissues beyond the scope of conventional ultrasound devices.
How does MAUI Imaging's technology differ from traditional ultrasound?
MAUI Imaging's CET uses unique reflection techniques to visualize anatomy through barriers, allowing for clearer and more comprehensive imaging, especially in challenging areas like the brain and lungs.
What is the significance of the FDA clearance for MAUI's devices?
The 510(k) FDA clearance for the MAUI K3900 device signifies its approval for commercial use, allowing healthcare professionals to utilize it for various examinations and procedures.
How is MAUI Imaging contributing to trauma care?
MAUI Imaging is collaborating with the U.S. Department of Defense to enhance trauma medicine capabilities, aiming to provide faster diagnosis and treatment in high-pressure environments.
